Bd receives fda 510(k) clearance for rapid point-of-care covid-19 test

New clia-waived test delivers digital results to support timely clinical decision-making franklin lakes, n.j. , july 30, 2025 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced it has received u.s. food and drug administration (fda) 510(k) clearance for the bd veritor™ system for sars-cov-2, a digital test designed to detect covid-19 antigens in symptomatic individuals in about 15 minutes at doctors' offices, urgent care centers, retail clinics and other convenient points of care.
BDX Ratings Summary
BDX Quant Ranking